Berns Paul L
SEC-identified person · CIK 1202769 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Kardigan, Inc. KARD | Director | filed 2026 - 2026 |
| Lyell Immunopharma, Inc. LYEL | Officer | filed 2025 - 2026 |
| Neumora Therapeutics, Inc. NMRA | Director · See Remarks | filed 2023 - 2026 |
| Metsera, Inc. MTSR | Director | filed 2025 - 2025 |
| Unity Biotechnology, Inc. UBX | Director | filed 2018 - 2024 |
| Eqrx, Inc. EQRX | Director | filed 2021 - 2023 |
| Jazz Pharmaceuticals plc JAZZ | Director | filed 2010 - 2021 |
| Vyne Therapeutics Inc. VYNE | Director | filed 2018 - 2019 |
| Anacor Pharmaceuticals, Inc. ANAC | Director · President and CEO | filed 2012 - 2016 |
| Xenoport INC XNPT | Director | filed 2006 - 2016 |
| Cellectar Biosciences, Inc. clrB | Director | filed 2014 - 2016 |
| Allos Therapeutics INC ALTH | Chief Executive Officer | filed 2006 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.